Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells.
- Author:
Dami AN
1
;
Kwangmi KIM
;
Jeongyun KIM
Author Information
1. Department of Nanobiomedical Science, Dankook University, Cheonan 330-714, Republic of Korea. jeongyunkim@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Microfluidic system;
HTDS;
Combinational chemotherapy;
PC-3;
TRAIL;
Curcumin
- MeSH:
Apoptosis;
Cell Culture Techniques;
Cell Line;
Curcumin;
Drug Evaluation, Preclinical*;
Drug Therapy*;
Humans;
Mass Screening;
Lab-On-A-Chip Devices;
Microfluidics*;
Prostatic Neoplasms*;
Syringes;
Tumor Necrosis Factor-alpha
- From:Biomolecules & Therapeutics
2014;22(4):355-362
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have developed a fully automated high throughput drug screening (HTDS) system based on the microfluidic cell culture array to perform combinational chemotherapy. This system has 64 individually addressable cell culture chambers where the sequential combinatorial concentrations of two different drugs can be generated by two microfluidic diffusive mixers. Each diffusive mixer has two integrated micropumps connected to the media and the drug reservoirs respectively for generating the desired combination without the need for any extra equipment to perfuse the solution such as syringe pumps. The cell array is periodically exposed to the drug combination with the programmed LabVIEW system during a couple of days without extra handling after seeding the cells into the microfluidic device and also, this device does not require the continuous generation of solutions compared to the previous systems. Therefore, the total amount of drug being consumed per experiment is less than a few hundred micro liters in each reservoir. The utility of this system is demonstrated through investigating the viability of the prostate cancer PC3 cell line with the combinational treatments of curcumin and tumor necrosis factor-alpha related apoptosis inducing ligand (TRAIL). Our results suggest that the system can be used for screening and optimizing drug combination with a small amount of reagent for combinatorial chemotherapy against cancer cells.
